From stem cells to billions of human insulin-producing cells
10 October 2014 | By The Harvard Stem Cell Institute
Giant step toward new diabetes treatment...
List view / Grid view
News
Positive results from Phase iib benralizumab study in severe asthma published in the Lancet Respiratory Medicine
10 October 2014 | By AstraZeneca
AstraZeneca announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell...
Medtech startup Embo Medical secures €3 million investment
9 October 2014 | By Embo Medical
Early-stage medical device company is developing minimally invasive embolization technology for the treatment of wide variety of diseases...
Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany
9 October 2014 | By Bone Therapeutics
Four German centres now approved to assess novel allogeneic regenerative therapy for the treatment of delayed union fractures...
Cardio3 Biosciences awarded preferred access rights to all Mayo Clinic Center for regenerative medicine portfolio
9 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the signing of a preferred access agreement with Mayo Clinic...
FDA grants Priority Review for Lucentis in diabetic retinopathy
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
DOW-COLORCON Alliance will commercialize next-generation HPMC excipient by year-end to help lower tablet manufacturing costs by up to 60 percent
9 October 2014 | By The Controlled Release Alliance of Dow Pharma & Food Solutions
The Controlled Release Alliance of Dow Pharma & Food Solutions and Colorcon Inc. announced that it is planning to have global commercial availability of its next-generation METHOCEL™ DC2 polymer by year end...
Bristol-Myers Squibb statement about Asunaprevir in the U.S.
9 October 2014 | By Bristol-Myers Squibb Company
Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States...
Record attendance for CHI’s Sixth Annual PEGS Europe Summit
9 October 2014 | By Cambridge Healthtech Institute
Largest European event for protein and antibody engineering returns to Lisbon...
New study shows UK public are largely unaware of stem cells as the potential uses are still being realised
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
Avacta extends Optim® 2 product family for even greater measurement flexibility
9 October 2014 | By kdm communications
Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes...
Micro Droplet Systems provide seamless production of monodispersed droplets
9 October 2014 | By kdm communications
Dolomite Microfluidics, a sister company to flow chemistry specialist Syrris, has developed an innovative range of Micro Droplet Systems for automatic, seamless production of monodispersed droplets...
B&W Tek announces new enhancements to NanoRam handheld Raman spectrometer
8 October 2014 | By B&W Tek
B&W Tek, is pleased to announce new enhancements to its NanoRam® handheld Raman spectrometer...
Recent developments keep Gilead ahead of the pack in HIV treatment market, says GlobalData Analyst
8 October 2014 | By GlobalData
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader...
Bristol-Myers Squibb statement on Sustiva (efavirenz) in the U.S.
8 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products...
